Matches in SemOpenAlex for { <https://semopenalex.org/work/W1644875105> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W1644875105 abstract "Introduction: In a small neoadjuvant study in patients with triple negative breast cancer (TNBC) the combination of eribulin plus carboplatin was effective, with a pathologic complete response rate of 43% following 4 cycles of treatment. Significant numbers of sporadic TNBC tumors are deficient in DNA repair capacity and share clinical and pathological features with hereditary BRCA1 mutant disease. PARP inhibitors have demonstrated synthetic lethality in cancer cells with defective DNA repair and have therapeutic potential for TNBC. In this study we describe the combination of PARP inhibitor E7449 with eribulin +/- carboplatin in preclinical models of TNBC.Methods: E7449, an orally available PARP inhibitor, was administered in combination with eribulin +/- carboplatin to 4 s.c. xenograft models of TNBC: MDA-MB-436 (BRCA1 mutant, PTEN deficient), MDA-MB-468 (BRCA wild type, PTEN deficient), HCC1806 and MDA-MB-231 (BRCA and PTEN wild type).Results and Discussion: Addition of E7449 to eribulin significantly delayed tumor progression in PTEN deficient MDA-MB-468 xenografts. In the BRCA1 mutant and PTEN deficient MDA-MB-436 xenograft model, combination of E7449 with eribulin enhanced antitumor activity versus eribulin alone. Similar potentiation was observed for carboplatin upon combination with E7449. Treatment of MDA-MB-436 xenografts with the triple combination of E7449 + eribulin + carboplatin was more efficacious than any double combination and was well tolerated at the doses examined. In contrast, no significant combination activity was observed for E7449 plus eribulin in the BRCA and PTEN wild type xenografts HCC1806 and MDA-MB-231, and similarly no potentiation of carboplatin was observed in an MDA-MB-231 xenograft. Notably, combination activity was observed in the BRCA1 mutant (MDA-MB-436) and PTEN deficient (MDA-MB-436 and MDA-MB-468) xenografts and not in the BRCA and PTEN wild-type models (HCC1806 and MDA-MB-231). Data from ongoing studies to evaluate the combination activity of E7449 + eribulin in patient-derived xenograft (PDx) models of TNBC will be presented at the meeting.Potential biomarkers of sensitivity to the combination are under investigation in both cell line xenograft and PDx models and will be described.Conclusion: The addition of E7449 to eribulin +/- carboplatin increased antitumor activity in a subset of TNBC models. Biomarker studies aimed at a better understanding of the underlying cause of sensitivity are underway. The preclinical data support assessment of E7449 + eribulin + carboplatin combination therapy in the current phase I/II clinical trial.Citation Format: Sharon McGonigle, Jiayi Wu, Donna Kolber-Simonds, Natalie C Twine, Jue-lon Shie, Noel Taylor, Sergei Agoulnik, Zoltan Dezso, Shannon McGrath, Mark Matijevic, Shanqin Xu, Galina Kuznetsov, Mary Woodall-Jappe, Kenichi Nomoto. Combination of the PARP inhibitor E7449 with eribulin +/- carboplatin in preclinical models of triple negative breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P5-06-03." @default.
- W1644875105 created "2016-06-24" @default.
- W1644875105 creator A5004534666 @default.
- W1644875105 creator A5008426990 @default.
- W1644875105 creator A5021756014 @default.
- W1644875105 creator A5033009316 @default.
- W1644875105 creator A5051146842 @default.
- W1644875105 creator A5055428383 @default.
- W1644875105 creator A5055966065 @default.
- W1644875105 creator A5056667399 @default.
- W1644875105 creator A5057114998 @default.
- W1644875105 creator A5066927624 @default.
- W1644875105 creator A5070503646 @default.
- W1644875105 creator A5078860162 @default.
- W1644875105 creator A5087463666 @default.
- W1644875105 creator A5090570108 @default.
- W1644875105 date "2015-04-30" @default.
- W1644875105 modified "2023-10-14" @default.
- W1644875105 title "Abstract P5-06-03: Combination of the PARP inhibitor E7449 with eribulin +/- carboplatin in preclinical models of triple negative breast cancer" @default.
- W1644875105 doi "https://doi.org/10.1158/1538-7445.sabcs14-p5-06-03" @default.
- W1644875105 hasPublicationYear "2015" @default.
- W1644875105 type Work @default.
- W1644875105 sameAs 1644875105 @default.
- W1644875105 citedByCount "0" @default.
- W1644875105 crossrefType "proceedings-article" @default.
- W1644875105 hasAuthorship W1644875105A5004534666 @default.
- W1644875105 hasAuthorship W1644875105A5008426990 @default.
- W1644875105 hasAuthorship W1644875105A5021756014 @default.
- W1644875105 hasAuthorship W1644875105A5033009316 @default.
- W1644875105 hasAuthorship W1644875105A5051146842 @default.
- W1644875105 hasAuthorship W1644875105A5055428383 @default.
- W1644875105 hasAuthorship W1644875105A5055966065 @default.
- W1644875105 hasAuthorship W1644875105A5056667399 @default.
- W1644875105 hasAuthorship W1644875105A5057114998 @default.
- W1644875105 hasAuthorship W1644875105A5066927624 @default.
- W1644875105 hasAuthorship W1644875105A5070503646 @default.
- W1644875105 hasAuthorship W1644875105A5078860162 @default.
- W1644875105 hasAuthorship W1644875105A5087463666 @default.
- W1644875105 hasAuthorship W1644875105A5090570108 @default.
- W1644875105 hasConcept C104317684 @default.
- W1644875105 hasConcept C121608353 @default.
- W1644875105 hasConcept C126322002 @default.
- W1644875105 hasConcept C182979987 @default.
- W1644875105 hasConcept C185592680 @default.
- W1644875105 hasConcept C190283241 @default.
- W1644875105 hasConcept C2775930923 @default.
- W1644875105 hasConcept C2776387010 @default.
- W1644875105 hasConcept C2776694085 @default.
- W1644875105 hasConcept C2776999253 @default.
- W1644875105 hasConcept C2777609662 @default.
- W1644875105 hasConcept C2778239845 @default.
- W1644875105 hasConcept C2779138821 @default.
- W1644875105 hasConcept C2780110267 @default.
- W1644875105 hasConcept C2781451048 @default.
- W1644875105 hasConcept C502942594 @default.
- W1644875105 hasConcept C530470458 @default.
- W1644875105 hasConcept C55493867 @default.
- W1644875105 hasConcept C71924100 @default.
- W1644875105 hasConcept C82381507 @default.
- W1644875105 hasConcept C86554907 @default.
- W1644875105 hasConcept C98274493 @default.
- W1644875105 hasConceptScore W1644875105C104317684 @default.
- W1644875105 hasConceptScore W1644875105C121608353 @default.
- W1644875105 hasConceptScore W1644875105C126322002 @default.
- W1644875105 hasConceptScore W1644875105C182979987 @default.
- W1644875105 hasConceptScore W1644875105C185592680 @default.
- W1644875105 hasConceptScore W1644875105C190283241 @default.
- W1644875105 hasConceptScore W1644875105C2775930923 @default.
- W1644875105 hasConceptScore W1644875105C2776387010 @default.
- W1644875105 hasConceptScore W1644875105C2776694085 @default.
- W1644875105 hasConceptScore W1644875105C2776999253 @default.
- W1644875105 hasConceptScore W1644875105C2777609662 @default.
- W1644875105 hasConceptScore W1644875105C2778239845 @default.
- W1644875105 hasConceptScore W1644875105C2779138821 @default.
- W1644875105 hasConceptScore W1644875105C2780110267 @default.
- W1644875105 hasConceptScore W1644875105C2781451048 @default.
- W1644875105 hasConceptScore W1644875105C502942594 @default.
- W1644875105 hasConceptScore W1644875105C530470458 @default.
- W1644875105 hasConceptScore W1644875105C55493867 @default.
- W1644875105 hasConceptScore W1644875105C71924100 @default.
- W1644875105 hasConceptScore W1644875105C82381507 @default.
- W1644875105 hasConceptScore W1644875105C86554907 @default.
- W1644875105 hasConceptScore W1644875105C98274493 @default.
- W1644875105 hasLocation W16448751051 @default.
- W1644875105 hasOpenAccess W1644875105 @default.
- W1644875105 hasPrimaryLocation W16448751051 @default.
- W1644875105 hasRelatedWork W1644875105 @default.
- W1644875105 hasRelatedWork W1655775240 @default.
- W1644875105 hasRelatedWork W2010832395 @default.
- W1644875105 hasRelatedWork W2057644750 @default.
- W1644875105 hasRelatedWork W2325431901 @default.
- W1644875105 hasRelatedWork W2394688475 @default.
- W1644875105 hasRelatedWork W2592766800 @default.
- W1644875105 hasRelatedWork W3091768466 @default.
- W1644875105 hasRelatedWork W3178688808 @default.
- W1644875105 hasRelatedWork W4220655812 @default.
- W1644875105 isParatext "false" @default.
- W1644875105 isRetracted "false" @default.
- W1644875105 magId "1644875105" @default.
- W1644875105 workType "article" @default.